Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells - PubMed (original) (raw)
Comparative Study
doi: 10.1038/sj.bmt.1705628. Epub 2007 Mar 12.
Affiliations
- PMID: 17351648
- DOI: 10.1038/sj.bmt.1705628
Comparative Study
Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells
J J A Coenen et al. Bone Marrow Transplant. 2007 May.
Abstract
Graft-versus-host-disease (GVHD) is the most common cause of poor outcome after allogeneic stem cell transplantation (SCT). Of late, exploitation of FOXP3(+) regulatory T-cell (T(REG)) function is emerging as a promising strategy in suppression of GVHD, while preserving graft-versus-leukemia (GVL). Cyclosporine and rapamycin reduce the expansion of effector T cells by blocking interleukin (IL)-2, but signaling by IL-2 is pivotal for T(REG) homeostasis. The resolution of GVHD is critically dependent on thymus-dependent reconstitution of the immunoregulatory system. Thus, there has been concern about the impact of blocking IL-2 signaling by immunosuppressive agents on T(REG) homeostasis. Here we demonstrate in a mouse model that in contrast to rapamycin, cyclosporine compromises not only the thymic generation of CD4(+)CD25(+)FoxP3(+) T cells but also their homeostatic behavior in peripheral immune compartments. Treatment with cyclosporine resulted in a sharp reduction of peripheral CD25(+)FoxP3(+) T cells in all immune compartments studied. Prolonged rapamycin treatment allowed for thymic generation of CD4(+)FoxP3(+) T cells, whereas treatment with cyclosporine led to a reduced generation of these cells. In conclusion, cyclosporine and rapamycin differentially affect homeostasis of CD4(+)FoxP3(+) T(REG) in vivo. As peripheral tolerance induction is a prerequisite for successful treatment outcome after allogeneic SCT, these findings are of potential clinical relevance.
Similar articles
- Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
Giorgini A, Noble A. Giorgini A, et al. J Leukoc Biol. 2007 Nov;82(5):1053-61. doi: 10.1189/jlb.0407227. Epub 2007 Aug 7. J Leukoc Biol. 2007. PMID: 17684039 - Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo.
Delgado M, Chorny A, Gonzalez-Rey E, Ganea D. Delgado M, et al. J Leukoc Biol. 2005 Dec;78(6):1327-38. doi: 10.1189/jlb.0605299. Epub 2005 Oct 4. J Leukoc Biol. 2005. PMID: 16204628 - CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation.
Zorn E. Zorn E. Semin Cancer Biol. 2006 Apr;16(2):150-9. doi: 10.1016/j.semcancer.2005.11.008. Epub 2006 Jan 23. Semin Cancer Biol. 2006. PMID: 16431128 Review. - TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets.
Pyzik M, Piccirillo CA. Pyzik M, et al. J Leukoc Biol. 2007 Aug;82(2):335-46. doi: 10.1189/jlb.1006644. Epub 2007 May 2. J Leukoc Biol. 2007. PMID: 17475784 - Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
Hess AD. Hess AD. Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 2):13-21. doi: 10.1016/j.bbmt.2005.11.002. Biol Blood Marrow Transplant. 2006. PMID: 16399597 Review.
Cited by
- Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research.
Son B, Lee W, Kim H, Shin H, Park HH. Son B, et al. Cell Death Dis. 2024 Sep 30;15(9):696. doi: 10.1038/s41419-024-07077-8. Cell Death Dis. 2024. PMID: 39349424 Free PMC article. Review. - Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis.
Cioccio J, Rakszawski K, Zheng H, Nickolich M, Naik S, Wirk B, Rybka W, Ehmann C, Silar B, Vajdic C, Shah N, Tuanquin L, Greiner R, Brown V, Hohl R, Claxton D, Mineishi S, Minagawa K, Shike H. Cioccio J, et al. Ann Hematol. 2023 Mar;102(3):613-620. doi: 10.1007/s00277-022-05077-2. Epub 2022 Dec 17. Ann Hematol. 2023. PMID: 36527460 - Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide.
Nakamae H. Nakamae H. Int J Hematol. 2022 Oct;116(4):465-481. doi: 10.1007/s12185-022-03428-3. Epub 2022 Aug 5. Int J Hematol. 2022. PMID: 35930118 - Harnessing the B Cell Response in Kidney Transplantation - Current State and Future Directions.
Anwar IJ, DeLaura IF, Gao Q, Ladowski J, Jackson AM, Kwun J, Knechtle SJ. Anwar IJ, et al. Front Immunol. 2022 Jun 9;13:903068. doi: 10.3389/fimmu.2022.903068. eCollection 2022. Front Immunol. 2022. PMID: 35757745 Free PMC article. Review. - Kinase Inhibition as Treatment for Acute and Chronic Graft-_Versus_-Host Disease.
Braun LM, Zeiser R. Braun LM, et al. Front Immunol. 2021 Nov 17;12:760199. doi: 10.3389/fimmu.2021.760199. eCollection 2021. Front Immunol. 2021. PMID: 34868001 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials